Skip to main content
Delfa

← All trials/NCT03013296

CompletedPhase NA

Delinieation of GIP's Effects During a Meal in Humans Using GIP Receptor Antagonisation (GA-4)

Asset

GLP-1 / incretin class catch-all

Listed sites

1

Recruiting sites

-

Actual enrollment

12

Study population

MASH / NAFLD / liver fibrosis

Eligibility highlights

Male

Primary endpoint

C-peptide levels

Registered trial locations

Locations reported to ClinicalTrials.gov for this trial snapshot. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT03013296
Org study IDUHG-CFD-GIPANTA-4

Timeline

Milestones

Study first posted2017-01-06estimated
Last update posted2019-06-04actual
Study start2016-10 (month precision)
Primary completion2017-07actual (month precision)
Study completion2018-09actual (month precision)

Assets

Investigational agents

Who this study enrolls

MASH / NAFLD / liver fibrosis

Who can enroll

Minimum age18 Years
Maximum age70 Years
SexMale
Healthy volunteersAccepted

Inclusion criteria

Normal kidney function, liver function and hemoglobin levels.

Exclusion criteria

Medication, Diabetes type 1 or 2, BMI > 27, first degree relatives with Type 2 Diabetes

Endpoints (1)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Glycemic / diabetes

1 endpoint
Primary/protocol endpoint

C-peptide levels

Time frame:180 minutes

descriptive

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 6, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 6, 2026 snapshot.